Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 478-486

  Rodriguez Pascual, Jesus ^a   Cheng, Elaine ^a   Maroto, Pablo ^b   Duran, Ignacio ^a  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Everolimus; MTOR inhibitors; Renal cell cancer; Ridaforolimus; Temsirolimus; Toxicity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CARBAMAZEPINE; CYTOCHROME P450 INHIBITOR; DEFOROLIMUS; EFAVIRENZ; EVEROLIMUS; GAMMA INTERFERON; INSULIN; METFORMIN; NEVIRAPINE; PHENOBARBITAL; PHOSPHATE; RIFAMPICIN; ROSIGLITAZONE; SULFONYLUREA; TEMSIROLIMUS;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW SUPPRESSION; CLINICAL PRACTICE; DIARRHEA; DRUG EFFICACY; DRY SKIN; ECZEMA; EUPHORIA; EVIDENCE BASED MEDICINE; FATIGUE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERICUM PERFORATUM; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN TREATMENT; INTERSTITIAL LUNG DISEASE; KIDNEY CARCINOMA; LEUKOPENIA; LIFESTYLE; LUNG FUNCTION TEST; MUCOSA INFLAMMATION; NAIL DISEASE; NAUSEA; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHATE DEFICIENCY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STOMATITIS; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA;

ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, RENAL CELL; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS;

EID: 77951282223     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32833760bf     Document Type: Review

References (39)

1. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998; 279:710-714.
2. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-1101.
3. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13:3109-3114.
4. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res 2009; 15:1428-1434.
5. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281. (Pubitemid 46849157)
6. Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every weeks to patients with advanced malignancies. J Clin Oncol 2008; 26:361-367.
7. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372:449-456.
8. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13:1084-1096.
9. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917-930.
10. Dudkin L, Dilling MB, Cheshire PJ, Harwood FC, Hollingshead M, Arbuck SG, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7:1758-1764.
11. Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177-189.
12. Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61:1527-1532.
13. McMahon LP, Yue W, Santen RJ, Lawrence JC Jr. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol Endocrinol 2005; 19:175-183.
14. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni JP, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-2347.
15. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22:909-918.
16. Duran I, Siu LL, Oza AM, Chung TB, Sturgeon J, Townsley CA, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42:1875-1880.
17. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19:1387-1392.
18. Maroto P, Hudes G, Dutcher J, White C, Krygowski M, Cincotta M, et al. A radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus. Eur J Cancer 2009; 7:426.
19. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16:525-537.
20. Tabernero J, Rojo F, Burris H, Casado E, Macarulla T, Jones S, et al. A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 2005; 23:3007.
21. Chawla SP, Sankhala KK, Chua V, Menendez LR, Eilber FC, Eckardt JJ, et al. A phase II study of AP23573 (an mTOR inhibitor) in patients (pts) with advanced sarcomas. ASCO Meeting Abstracts 2005; 23:9068.
22. Feldman E, Giles F, Roboz G, Yee K, Curcio T, Rivera VM, et al. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. ASCO Meeting Abstracts 2005; 23:6631.
23. Mita MM, Rowinsky EK, Goldston ML, Mita AC, Chu Q, Syed S, et al. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. ASCO Meeting Abstracts 2004; 22:3076.
24. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated hemoglobin assay. N Engl J Med 1984; 310:341-346.
25. Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25:608-613.
26. Van de Laar FA. Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag 2008; 4:1189-1195.
27. Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004; 53:393-399.
28. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004; 140:644-649.
29. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-732.
30. White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J Thorac Oncol 2009; 4:1357-1363.
31. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995; 104:1-8.
32. Boni JP, Leister C, Burns J, Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008; 98:1797-1802.
33. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol 2007; 47:1430-1439.
34. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Allison MJ, Schmouder RL. Pharmacokinetic interaction between verapamil and everolimus in healthy subjects. Br J Clin Pharmacol 2005; 60:434-437.
35. Kovarik JM, Beyer D, Schmouder RL. Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 2006; 27:421-426.
36. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002; 42:95-99.
37. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744.
38. EMEA: Afinitor: European Public Assesment Report. In, http:// www.emea.europa.eu/humandocs/Humans/EPAR/afinitor/afinitor.htm, 2009.
39. Pea F, Baccarani U, Tavio M, Cojutti P, Adani GL, Londero A, et al. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. Ann Pharmacother 2008; 42:1711-1716.